Trevi Therapeutics, Inc. IPO Research Information

Trevi Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Trevi Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Trevi Therapeutics, Inc.	TRVI - NASDAQ	$14.00-$16.00	$10.00	$9.50	5.5 million	5/7/2019
Underwriter(s): SVB Leerink, Stifel, BMO Capital
Co-Manager(s): Needham
Industry: Health Care
Filing(s): Filed 2019-04-05 Terms Added 2019-04-22

Trevi Therapeutics, Inc. Quote & Chart - Click for current quote - TRVI

About Trevi Therapeutics, Inc. (adapted from Trevi Therapeutics, Inc. prospectus):
They are a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "TRVI" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.